CDK12 and prostate carcinoma: An important role in cell cycle is carried out by Cyclin-dependent kinase 12 (CDK12), which can be found mutated in a subgroup of prostate cancer patients with infiltration of CD4+forkhead boxP3 (FOXP3)- T-cells and neoantigens exposition, thus resulting in an exalted immunotherapy response [66].